Bridging the Gaps in Lung Cancer: 6 Month Update Winter Lung Cancer Conference 2025 - Episode 7
New Targeted Approaches in Unresectable Early-Stage NSCL
Panelists discuss how osimertinib has been approved for patients with unresectable, EGFR-mutated stage III non–small cell lung cancer (NSCLC) following chemoradiation, based on the LAURA trial, which demonstrated a significant improvement in progression-free survival. In clinical practice, osimertinib is administered as consolidation therapy until disease progression or unacceptable toxicity. Ongoing studies like PACIFIC-9 and PACIFIC-8 are exploring the efficacy of combining durvalumab with other agents, potentially influencing future chemo-immunotherapy strategies in advanced NSCLC.
Video Player is loading.
Video content above is prompted by the following:
- Please discuss the role of osimertinib in patients with unresectable NSCLC.
- Briefly comment on the latest data from the LAURA study and recent approval (September 2024) of osimertinib in this space. (Ramalingam SS, et al. ASCO 2024. LBA4; FDA.gov, FDA approves osimertinib for unresectable NSCLC)
- How are you incorporating the LAURA regimen into your practice, and what is your recommended duration of therapy for patients?
- How do data from trials like PACIFIC-9 and PACIFIC-8 shape your approach to chemo-immunotherapy combinations in advanced NSCLC?
